Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts

Current therapeutic approaches to treatment of patients with bulky cervical cancer are based on conventional in situ ablative modalities including cisplatin-based chemotherapy and radiation therapy. The 5-year survival of patients with nonresectable disease is dismal. Because over 99% of squamous cervical cancer is caused by persistent infection with an oncogenic strain of human papillomavirus (HPV), particularly type 16 and viral oncoproteins E6 and E7 are functionally required for disease initiation and persistence, HPV-targeted immune strategies present a compelling opportunity in which to demonstrate proof of principle. Sublethal doses of radiation and chemotherapeutic agents have been shown to have synergistic effect in combination with either vaccination against cancer-specific antigens, or with passive transfer of tumor-specific cytotoxic T lymphocytes (CTLs). Here, we explored the combination of low-dose radiation therapy with DNA vaccination with calreticulin (CRT) linked to the mutated form of HPV-16 E7 antigen (E7(detox)), CRT/E7(detox) in the treatment of E7-expressing TC-1 tumors. We observed that TC-1 tumor-bearing mice treated with radiotherapy combined with CRT/E7(detox) DNA vaccination generated significant therapeutic antitumor effects and the highest frequency of E7-specific CD8+ T cells in the tumors and spleens of treated mice. Furthermore, treatment with radiotherapy was shown to render the TC-1 tumor cells more susceptible to lysis by E7-specific CTLs. In addition, we observed that treatment with radiotherapy during the second DNA vaccination generated the highest frequency of E7-specific CD8+ T cells in the tumors and spleens of TC-1 tumor-bearing mice. Finally, TC-1 tumor-bearing mice treated with the chemotherapy in combination with radiation and CRT/E7(detox) DNA vaccination generate significantly enhanced therapeutic antitumor effects. The clinical implications of the study are discussed.

[1]  J. Gulley,et al.  A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229). , 2006, Clinical breast cancer.

[2]  L. Zitvogel,et al.  Immunological aspects of cancer chemotherapy , 2008, Nature Reviews Immunology.

[3]  Kevin Camphausen,et al.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy , 2006 .

[4]  J. Sin,et al.  Therapeutic Synergy of Human Papillomavirus E7 Subunit Vaccines plus Cisplatin in an Animal Tumor Model: Causal Involvement of Increased Sensitivity of Cisplatin-Treated Tumors to CTL-Mediated Killing in Therapeutic Synergy , 2007, Clinical Cancer Research.

[5]  P. Srivastava,et al.  Calreticulin, a Peptide-binding Chaperone of the Endoplasmic Reticulum, Elicits Tumor- and Peptide-specific Immunity , 1999, The Journal of experimental medicine.

[6]  F. Guarnieri,et al.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.

[7]  T. Wu,et al.  Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. , 2001, The Journal of clinical investigation.

[8]  Chung-Pin Li,et al.  Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma , 2005, Journal of immunotherapy.

[9]  R. Kurman,et al.  Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. , 1999, Human gene therapy.

[10]  K. Itoh,et al.  Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA‐A24+ HRPC patients , 2005, The Prostate.

[11]  H. Christiansen,et al.  Effect of Radiation on Gene Expression of Rat Liver Chemokines: In Vivo and In Vitro Studies , 2008, Radiation research.

[12]  Z. Xiang,et al.  Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. , 2000, Virology.

[13]  J. Gribben,et al.  Unexpected Association between Induction of Immunity to the Universal Tumor Antigen CYP1B1 and Response to Next Therapy , 2005, Clinical Cancer Research.

[14]  T. Wu,et al.  Comparison of HPV DNA vaccines employing intracellular targeting strategies , 2004, Gene Therapy.

[15]  C. Chuang,et al.  Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell–Mediated Antitumor Immunity Induced by DNA Vaccination , 2008, Clinical Cancer Research.

[16]  J. Schlom,et al.  Sublethal Irradiation of Human Tumor Cells Modulates Phenotype Resulting in Enhanced Killing by Cytotoxic T Lymphocytes , 2004, Cancer Research.

[17]  S. Gerber,et al.  Radiation-Induced IFN-γ Production within the Tumor Microenvironment Influences Antitumor Immunity1 , 2008, The Journal of Immunology.

[18]  T. Wu,et al.  Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. , 2000, Cancer research.

[19]  T. Wu,et al.  Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency. , 2007, Vaccine.

[20]  M. Michalak,et al.  Heat Shock-sensitive Expression of Calreticulin. , 1995, The Journal of Biological Chemistry.

[21]  J. Sin,et al.  Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic anti-tumor activity. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[22]  J. Neefjes,et al.  TAP‐translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin , 1997, European journal of immunology.

[23]  J. Bertho,et al.  Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. , 1997, International journal of radiation biology.

[24]  R. Roden,et al.  Preventative and therapeutic vaccines for cervical cancer , 2003, Expert review of vaccines.

[25]  P. Nash,et al.  Calreticulin: not just another calcium-binding protein , 1994, Molecular and Cellular Biochemistry.

[26]  T. Wu,et al.  Preventive and therapeutic HPV vaccines. , 2007, Current opinion in investigational drugs.

[27]  G. Bepler,et al.  Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[28]  P. Cresswell,et al.  Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. , 1996, Immunity.

[29]  J. Schlom,et al.  Combination Chemotherapy and Radiation of Human Squamous Cell Carcinoma of the Head and Neck Augments CTL-Mediated Lysis , 2006, Clinical Cancer Research.

[30]  C. N. Coleman,et al.  Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer , 2005, Clinical Cancer Research.